Edgewise Therapeutics Inc
$ 24.62
-6.57%
29 Dec - close price
- Market Cap 2,606,481,000 USD
- Current Price $ 24.62
- High / Low $ 26.54 / 24.57
- Stock P/E N/A
- Book Value 5.28
- EPS -1.57
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.30 %
- 52 Week High 30.48
- 52 Week Low 10.60
About
Edgewise Therapeutics, Inc. is a biopharmaceutical company based in Boulder, Colorado, dedicated to developing innovative small molecule therapies aimed at musculoskeletal diseases. Utilizing its proprietary technology platform, Edgewise focuses on delivering precision medicine solutions that address significant unmet medical needs in muscle disorders and bone injuries. The company's robust pipeline of transformative therapies positions it to significantly improve patient outcomes and reshape treatment paradigms in orthopedics, reflecting its strong commitment to advancing the field of musculoskeletal health.
Analyst Target Price
$38.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-02-23 |
| Reported EPS | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 | -0.36 | -0.31 |
| Estimated EPS | -0.4009 | -0.42 | -0.4211 | -0.4222 | -0.37 | -0.34 | -0.39 | -0.43 | -0.4 | -0.4 | -0.36 | -0.34 |
| Surprise | 0.0109 | 0.08 | -0.0089 | 0.0022 | 0.01 | 0 | 0.06 | -0.04 | -0.01 | 0.06 | 0 | 0.03 |
| Surprise Percentage | 2.7189% | 19.0476% | -2.1135% | 0.5211% | 2.7027% | 0% | 15.3846% | -9.3023% | -2.5% | 15% | 0% | 8.8235% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EWTX
2025-12-26 03:08:53
Edgewise Therapeutics announced the completion of Parts B and C and positive interim safety results from Part D of its Phase 2 CIRRUS-HCM trial for EDG-7500 in hypertrophic cardiomyopathy. The drug, a cardiac sarcomere modulator, was generally well tolerated with no clinically meaningful reductions in LVEF, differentiating it from existing therapies. The company is on track for full Part D data in Q2 2026 and Phase 3 initiation in Q4 2026.
2025-12-25 13:08:53
Edgewise Therapeutics (EWTX) has seen a significant surge, with its stock climbing 26% in one day and over 80% in the last three months, reaching a share price of $27.29. Despite this momentum, the company's price-to-book ratio of 5.2x suggests it is inexpensive compared to direct peers but elevated against the broader pharmaceuticals industry, indicating the market anticipates high future growth. Investors should consider potential clinical trial setbacks and the prolonged path to revenue for its pipeline drugs.
2025-12-25 06:08:53
Edgewise Therapeutics (NASDAQ: EWTX) saw its stock surge nearly 26% after reporting positive interim data from its Phase 2 clinical trial of EDG-7500, a drug designed to treat hypertrophic cardiomyopathy (HCM). The trial showed clinical activity across significant HCM disease markers with a favorable safety profile. The company also announced that it has exceeded its year-end enrollment goal for the ongoing Part D of the trial.
2025-12-25 05:08:36
Edgewise Therapeutics Inc. (NASDAQ: EWTX) stock soared on Wednesday after the company provided updates on its CIRRUS-HCM Phase 2 trial of EDG-7500, designed to treat hypertrophic cardiomyopathy (HCM). The trial showed clinical activity across key HCM markers with a favorable safety profile, and the company remains on track to deliver comprehensive efficacy and safety data in Q2 2026, advancing towards Phase 3 trial initiation by the end of 2026. This news comes shortly after its competitor, Cytokinetics, received FDA approval for their oHCM treatment, Myqorzo.
2025-12-24 17:09:28
Edgewise Therapeutics (NASDAQ: EWTX) stock surged on December 24, 2025, after providing a positive update on its EDG-7500 investigational therapy for hypertrophic cardiomyopathy (HCM). The company announced favorable interim safety observations from Part D of its Phase 2 CIRRUS-HCM trial, specifically regarding left ventricular ejection fraction (LVEF) stability and arrhythmia monitoring. Despite one reported adverse event of new-onset atrial fibrillation (AF) deemed unrelated to the study drug, the update, occurring shortly after the FDA approval of a competitor's HCM therapy, was seen by many as a de-risking moment for Edgewise.
2025-12-24 15:09:28
Edgewise Therapeutics (EWTX) saw its stock rise by approximately 17% after releasing updated interim data from a mid-stage trial for EDG-7500. This experimental therapy is designed to treat hypertrophic cardiomyopathy, a genetic heart disorder. The positive trial results indicate progress for the Boulder, Colorado-based biopharmaceutical company.
